LRA Statement: Potential Lupus Nephritis Drug Voclosporin Granted Priority Review by the U.S. FDA
NEW YORK, NY. July 22, 2020. The Lupus Research Alliance congratulates Aurinia Pharmaceuticals Inc. on acceptance of its NDA filing and priority review designation by the U.S. Food and Drug Administration for its investigational drug voclosporin for lupus nephritis. A serious inflammation of the kidneys, lupus nephritis is one of the most common complications of […]
2018 Distinguished Innovator Awardees Named by Lupus Research Alliance
NEW YORK, NY. December 20. The Lupus Research Alliance is proud to announce the 2018 recipients of the Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity: Nir Hacohen, PhD (right) and Vijay Kuchroo, DVM, PhD (left). Dr. Hacohen is seeking better ways to treat lupus kidney disease, the major cause of illness and […]
Low-Dose Chemotherapy May Help Lupus Nephritis
February 22, 2021 In a recent study published in Arthritis & Rheumatology, LRA-funded researcher Dr. Xian Zhang found that a low dose of the chemotherapy drug topotecan reduced the inflammation and kidney damage of lupus nephritis in mice with lupus. Topotecan was as effective as high doses of cyclophosphamide, another chemotherapy that’s currently used to […]
Summary Highlights of Important Research Presented at ACR Convergence 2023
November, 2023 At the recent ACR Convergence 2023, the annual meeting of the American College of Rheumatology, important lupus clinical trial data and breakthrough foundational research were presented. Following are highlights of work funded by the Lupus Research Alliance or supported in partnership with industry through our clinical affiliate Lupus Therapeutics. CAR-T Cell Therapy is […]
Reducing B Cells with Modified CAR T Cells is an Effective Treatment of Experimental Lupus: Shows Study Supported by Lupus Research Alliance
NEW YORK, NY. March 6, 2019. Depleting the number of harmful B cells with a novel immunotherapy that employs modified T cells may offer an effective strategy to treat lupus, according to a new study funded by the Lupus Research Alliance. These findings offer a renewed optimism for the elimination of B cells to provide […]
Promising New Lupus Treatments Highlighted ACR Annual Meeting
Results of clinical trials testing potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2020. These studies include phase I trials, which test for side effects and a safe dosage; larger phase II trials, which test for effectiveness and further gauge safety; and large phase III trials, which confirm […]
New Treatment Approaches Supported by LRA Were Highlighted at LUPUS 2019
April 11, 2019 The bacteria that cause urinary tract infections may trigger lupus flares, a former Alzheimer’s disease therapy has shown promising results in research models—these are just some of the findings presented by Lupus Research Alliance-funded scientists at the 13th International Congress on Systematic Lupus Erythematosus (LUPUS 2019), held in San Francisco. Here are […]
LRA Congratulates GSK on FDA Approval of Benlysta® (belimumab) for Children with Lupus Nephritis
NEW YORK, NY. July 27, 2022. The Lupus Research Alliance (LRA) is pleased to share that the U.S. Food and Drug Administration (FDA) has approved belimumab (Benlysta®) as the first-ever treatment specifically indicated for children aged 5 to 17 with lupus nephritis. Belimumab is already approved by the FDA to treat lupus nephritis in adults […]
Lupus Research Alliance Pleased to Share Positive News about Potential Drug for Lupus Nephritis
NEW YORK, NY. June 11, 2019. The Lupus Research Alliance is pleased to share positive topline results from a Phase 2 clinical study of a potential new treatment for proliferative lupus nephritis, the most severe form of kidney damage caused by lupus. Genentech, a member of the Roche Group, reported that at one year their […]
New Approach to Treating Lupus Nephritis
February 6, 2019 Scientists partly funded by the Lupus Research Alliance have found a potential new way to protect the kidneys in patients with lupus. A study led by Dr. Vicki Rubin Kelley of Brigham and Women’s Hospital in Boston, Massachusetts, suggests that blocking a molecule made by some cells in the kidney could reduce […]